FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and ...
Fibrobiologics Inc. has filed an IND application with the FDA seeking to begin first-in-human trials of CYPS-317, an investigational allogeneic fibroblast spheroid-based therapy for the treatment of ...
Phycin has been selected to receive an award through the ReGen Valley Tech Hub Call for Commercialization Resources, marking ...
HONG KONG SAR - EQS Newswire - 30 December 2025 - Uni-Bio Science Group Limited ("Uni-Bio Science Group", "Uni-Bio" or "the Group") is pleased to announce the official signing of a tripartite ...
FibroBiologics is pursuing a development program for FSdC spheroids with the goal of advancing to clinical trials. The data includes comprehensive preclinical pharmacology and efficacy assessments ...
TipRanks on MSN
FibroBiologics announces preclinical results for FSDC
FibroBiologics (FBLG) announced preclinical results for FSdC, an investigational FSdC spheroid-based therapy, demonstrating superior improvement ...
Experiments reveal that a time-dependent epistatic interaction influences how mice respond to opioids, and that intracellular fibroblast growth factors also influence opioid sensitivity.
FibroBiologics submits IND application with US FDA to initiate clinical trials of CYPS317 in psoriasis patients: Houston Saturday, January 3, 2026, 11:00 Hrs [IST] FibroBiologics ...
Summary • FibroBiologics, Inc. (FBLG) shares increased 21% in pre-market trading to $0.2934 following an FDA IND application submission.• The IND application is for CYPS317, a therapy aimed at ...
The clinical-stage biotechnology company is seeking regulatory clearance to begin clinical trials of CYPS317, an allogeneic ...
FibroBiologics is pursuing a development program for CYPS317 with the goal of advancing first-in-human clinical trials following FDA review of the IND filing. The IND submission includes comprehensive ...
FibroBiologics (FBLG) announced the filing of a Phase 1/2 Investigational New Drug application with the U.S. Food and Drug Administration seeking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback